InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,296.79
(
-0.01%
)
US TECH 100
22,458.00
(
-0.06%
)
Dow Jones
44,342.19
(
-0.32%
)
Brent Oil
68.69
(
0.00%
)
Bitcoin
117,769.02
(
-0.16%
)
Post# of 255703
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 121789
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 238735

Friday, 09/24/2021 3:57:07 PM

Friday, September 24, 2021 3:57:07 PM

Post# of 255703
PFE gains royalty on MRK’s Vaxneuvance/V114 pneumococcal vaccine:

https://www.fiercepharma.com/vaccines/pfizer-merck-settle-patent-dispute-next-gen-pneumococcal-shots

In a settlement this week in the U.S. federal court in Delaware, Merck and Pfizer agreed to dismiss patent claims against one another. Under the deal, Merck will pay Pfizer 7.25% of its net sales from pneumococcal conjugate shots worldwide through the end of 2026… After that, the company will owe a 2.5% royalty to its New York rival through the end of 2035…

The royalty is based on the settlement of patent litigation pertaining to conjugated vaccines.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up